Latest Headlines

Latest Headlines

Novavax jumps on positive PhII for RSV vaccine

he vaccine works by immunizing women in their childbearing years, causing them to pass on protective antibodies to guard infants. Now it's on to a pivotal trial.

Upstart Valor launches with plans to develop armed antibody cancer drugs

Some 19 months following his abrupt departure from the helm at Novavax, Rahul Singhvi is back with a new start-up with plans to develop a trio of armed-antibody cancer drugs.

Novavax reports positive avian flu vaccine results

Novavax enjoyed a bump in its stock--a climb of 4.9%--after reporting positive results from two Phase I trials of its avian influenza vaccine candidate, Bloomberg reports. Novavax closed Friday at $2.35; shares have risen 87% this year.

Novavax teams up to fight malaria

Novavax, CPL Biologicals and the International Centre for Genetic Engineering and Biotechnology will team up to develop a malaria vaccine in India.

Bird flu vaccine hits the clinic

Novavax saw a climb in its share value on the announcement that it has started enrollment of a Phase I clinical trial of its A/H5N1 vaccine to prevent bird flu.

Novavax gets a new CEO

Rockville-based Novavax has announced that Stanley Erck, its former executive chairman, is taking over as the company's new CEO. Prior to joining Novavax, Erck was CEO of Iomai Corporation, which

Interview: Novavax's CEO discusses HHS flu vaccine funding

Earlier this week, the HHS doubled down on new vaccine technology. The government granted Maryland-based Novavax a contract worth up to $179.1 million, while Cranbury, NJ's VaxInnate picked up a

Novavax, VaxInnate win $215M to develop better pandemic vaccines

The feds drive to whip up a bigger, faster supply of flu vaccine to fight pandemics has triggered a pair of new contracts initially totaling $215 million for Novavax and VaxInnate. Novavax shares

FDA lifts hold on Novavax RSV vaccine trial

Shares of Novavax ($NVAX) surged this morning on the news that the FDA has lifted its clinical hold on a Phase I study of an experimental RSV vaccine. Back in November the biotech reported that it

Novavax reports mild response in PhII seasonal flu trial

Shares of Novavax were buoyed slightly by the news that its mid-stage trial of a closely-watched seasonal flu vaccine demonstrated significant immunogenicity against one of three flu strains among